Profund Advisors LLC grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 43.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,024 shares of the biopharmaceutical company’s stock after purchasing an additional 23,476 shares during the quarter. Profund Advisors LLC’s holdings in Bristol-Myers Squibb were worth $5,008,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in the company. Ilmarinen Mutual Pension Insurance Co bought a new position in Bristol-Myers Squibb during the third quarter worth $12,880,000. Psagot Investment House Ltd. increased its position in Bristol-Myers Squibb by 4.6% during the third quarter. Psagot Investment House Ltd. now owns 4,038 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 178 shares during the period. Colony Group LLC increased its position in Bristol-Myers Squibb by 43.4% during the third quarter. Colony Group LLC now owns 165,312 shares of the biopharmaceutical company’s stock worth $8,383,000 after acquiring an additional 50,038 shares during the period. Voya Financial Advisors Inc. increased its position in Bristol-Myers Squibb by 2.7% during the third quarter. Voya Financial Advisors Inc. now owns 14,538 shares of the biopharmaceutical company’s stock worth $730,000 after acquiring an additional 379 shares during the period. Finally, Redpoint Investment Management Pty Ltd increased its position in Bristol-Myers Squibb by 0.7% during the third quarter. Redpoint Investment Management Pty Ltd now owns 115,673 shares of the biopharmaceutical company’s stock worth $5,866,000 after acquiring an additional 820 shares during the period. 77.88% of the stock is currently owned by institutional investors.
A number of brokerages recently issued reports on BMY. ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Monday, March 9th. William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Friday, February 14th. Gabelli began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, November 27th. They set a “buy” rating on the stock. Argus upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Friday, December 13th. Finally, Citigroup upgraded shares of Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target on the stock in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Buy” and a consensus target price of $62.08.
Shares of NYSE:BMY traded up $2.90 on Thursday, hitting $52.25. The stock had a trading volume of 21,599,571 shares, compared to its average volume of 16,155,833. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $68.34. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.37 and a current ratio of 1.60. The firm’s 50 day moving average price is $60.09 and its 200-day moving average price is $58.38. The company has a market capitalization of $111.16 billion, a price-to-earnings ratio of 23.86, a price-to-earnings-growth ratio of 0.96 and a beta of 0.78.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.34. Bristol-Myers Squibb had a net margin of 13.15% and a return on equity of 31.85%. The company had revenue of $7.95 billion for the quarter, compared to the consensus estimate of $6.20 billion. During the same quarter in the previous year, the company earned $0.94 EPS. The firm’s revenue for the quarter was up 33.0% compared to the same quarter last year. As a group, sell-side analysts predict that Bristol-Myers Squibb Co will post 6.15 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Friday, April 3rd will be issued a $0.45 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $1.80 dividend on an annualized basis and a dividend yield of 3.44%. Bristol-Myers Squibb’s dividend payout ratio is 38.38%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: What are popular range trading strategies?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.